Last reviewed · How we verify
BUPROPION
BUPROPION is a drug. It is currently FDA-approved (first approved 1985) for Treatment of Major Depressive Disorder (MDD), Prevention of Seasonal Affective Disorder (SAD).
Bupropion is a small molecule inhibitor that acts as a dopamine transporter inhibitor. It has been studied for various conditions, including nicotine dependence, weight management, and endometrial cancer, often in combination with nicotine replacement therapies.
At a glance
| Generic name | BUPROPION |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
- Treatment of Major Depressive Disorder (MDD)
- Prevention of Seasonal Affective Disorder (SAD)
Boxed warnings
- WARNING: SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older [see Warnings and Precautions (5.1) ]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. ( 5.1 ) Monitor for worsening and emergence of suicidal thoughts and behaviors. ( 5.1 )
Common side effects
- Dry mouth
- Headache
- Nausea
- Insomnia
- Pharyngitis
- Dizziness
- Abdominal pain
- Agitation
- Infection
- Constipation
- Anxiety
- Myalgia
Serious adverse events
- Seizures
- Vomiting
- Sleep disturbances
- Rash
Key clinical trials
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (PHASE1)
- Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) (PHASE2, PHASE3)
- Preoperative Weight Loss for Open Abdominal Wall Reconstruction (NA)
- A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (PHASE1, PHASE2)
- Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (PHASE1)
- Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects (PHASE1)
- A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity (PHASE1)
- Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BUPROPION CI brief — competitive landscape report
- BUPROPION updates RSS · CI watch RSS
Frequently asked questions about BUPROPION
What is BUPROPION?
What is BUPROPION used for?
When was BUPROPION approved?
What development phase is BUPROPION in?
What are the side effects of BUPROPION?
Related
- Indication: Drugs for Treatment of Major Depressive Disorder (MDD)
- Indication: Drugs for Prevention of Seasonal Affective Disorder (SAD)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing